Targeting the EGFR/RAS/RAF signaling pathway in anticancer research: a recent update on inhibitor design and clinical trials (2020–2023)

References

• Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol. 2001;2(2):127–137. doi: 10.1038/35052073
   PubMed Web of Science ®Google Scholar
• Gschwind A, Fischer OM, Ullrich A. The discovery of receptor tyrosine kinases: targets for cancer therapy. Nat Rev Cancer. 2004;4(5):361–370. doi: 10.1038/nrc1360
   PubMed Web of Science ®Google Scholar
• Burgess AW. EGFR family: structure physiology signalling and therapeutic targets †. Growth Factors. 2008;26(5):263–274. doi: 10.1080/08977190802312844
   PubMed Web of Science ®Google Scholar
• Schlessinger J, Lemmon MA. Nuclear signaling by receptor tyrosine kinases: the first robin of spring. Cell. 2006;127(1):45–48. doi: 10.1016/j.cell.2006.09.013
   PubMed Web of Science ®Google Scholar
• Scaltriti M, Baselga J. The epidermal growth factor receptor pathway: a model for targeted therapy. Clin Cancer Res. 2006;12(18):5268–5272. doi: 10.1158/1078-0432.CCR-05-1554
   PubMed Web of Science ®Google Scholar
• Mendelsohn J, Baselga J. Epidermal growth factor receptor targeting in cancer. Semin Oncol. 2006;33(4):369–385. doi: 10.1053/j.seminoncol.2006.04.003
   PubMed Web of Science ®Google Scholar
• Hynes NE, MacDonald G. ErbB receptors and signaling pathways in cancer. Curr Opin Cell Biol. 2009;21(2):177–184. doi: 10.1016/j.ceb.2008.12.010
   PubMed Web of Science ®Google Scholar
• Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer. 2005;5(5):341–354. doi: 10.1038/nrc1609
   PubMed Web of Science ®Google Scholar
• Klapper LN, Kirschbaum MH, Seta M, et al. Biochemical and clinical implications of the ErbB/HER signaling network of growth factor receptors. Adv Cancer Res. 1999;77:25–79. Elsevier.
   Web of Science ®Google Scholar
• Heldin C-H. Dimerization of cell surface receptors in signal transduction. Cell. 1995;80(2):213–223. doi: 10.1016/0092-8674(95)90404-2
   PubMed Web of Science ®Google Scholar
• Yarden Y, Schlessinger J. Epidermal growth factor induces rapid, reversible aggregation of the purified epidermal growth factor receptor. Biochemistry. 1987;26(5):1443–1451. doi: 10.1021/bi00379a035
   PubMed Web of Science ®Google Scholar
• Press MF, Lenz H-J. Egfr, her2 and vegf pathways. Drugs. 2007;67(14):2045–2075. doi: 10.2165/00003495-200767140-00006
   PubMed Web of Science ®Google Scholar
• Kovacs E, Zorn JA, Huang Y, et al. A structural perspective on the regulation of the epidermal growth factor receptor. Annu Revi Biochem. 2015;84(1):739–764. doi: 10.1146/annurev-biochem-060614-034402
   PubMedGoogle Scholar
• Salomon DS, Brandt R, Ciardiello F, et al. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol. 1995;19(3):183–232. doi: 10.1016/1040-8428(94)00144-I
   PubMed Web of Science ®Google Scholar
• Sharma SV, Bell DW, Settleman J, et al. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer. 2007;7(3):169–181. doi: 10.1038/nrc2088
   PubMed Web of Science ®Google Scholar
• Yatabe Y, Mitsudomi T. Epidermal growth factor receptor mutations in lung cancers. Pathol Int. 2007;57(5):233–244. doi: 10.1111/j.1440-1827.2007.02098.x
   PubMed Web of Science ®Google Scholar
• Herbst RS, Langer CJ. Epidermal growth factor receptors as a target for cancer treatment: the emerging role of IMC-C225 in the treatment of lung and head and neck cancers. Semin Oncol. 2002;29(1):27–36. doi: 10.1053/sonc.2002.31525
   PubMed Web of Science ®Google Scholar
• Normanno N, Bianco C, De Luca A, et al. The role of EGF-related peptides in tumor growth. Front Biosci. 2001;6(1):685–707. doi: 10.2741/Normano
   Google Scholar
• Gazdar A. Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors. Oncogene. 2009;28(S1):S24. doi: 10.1038/onc.2009.198
   PubMedGoogle Scholar
• Hsu PC, Jablons DM, Yang CT, et al. Epidermal growth factor receptor (EGFR) pathway, yes-associated protein (YAP) and the regulation of programmed death-ligand 1 (PD-L1) in non-small cell lung cancer (NSCLC). Int J Mol Sci. 2019 Aug 5;20(15):3821. doi: 10.3390/ijms20153821
   PubMed Web of Science ®Google Scholar
• Batra SK, Castelino-Prabhu S, Wikstrand CJ, et al. Epidermal growth factor ligand-independent, unregulated, cell-transforming potential of a naturally occurring human mutant EGFRvIII gene. Cell Growth Differ: Mol Biol J Am Ass Cancer Res. 1995 Oct;6(10):1251–1259.
   Google Scholar
• Moscatello DK, Holgado-Madruga M, Emlet DR, et al. Constitutive activation of phosphatidylinositol 3-kinase by a naturally occurring mutant epidermal growth factor receptor. J Biol Chem. 1998 Jan 2;273(1):200–206. doi: 10.1074/jbc.273.1.200
   PubMed Web of Science ®Google Scholar
• Huang PH, Mukasa A, Bonavia R, et al. Quantitative analysis of EGFRvIII cellular signaling networks reveals a combinatorial therapeutic strategy for glioblastoma. Proc Natl Acad Sci USA. 2007 Jul 31;104(31):12867–12872. doi: 10.1073/pnas.0705158104
   PubMed Web of Science ®Google Scholar
• Zhang YL, Yuan JQ, Wang KF, et al. The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis. Oncotarget. 2016 Nov 29;7(48):78985–78993. doi: 10.18632/oncotarget.12587
   PubMedGoogle Scholar
• Harrison PT, Vyse S, Huang PH. Rare epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer. Semin Cancer Biol. 2020 Apr;61:167–179. doi: 10.1016/j.semcancer.2019.09.015
   PubMed Web of Science ®Google Scholar
• Martinelli E, Ciardiello D, Martini G, et al. Implementing anti-epidermal growth factor receptor (EGFR) therapy in metastatic colorectal cancer: challenges and future perspectives. Ann Oncol. 2020 Jan;31(1):30–40. doi: 10.1016/j.annonc.2019.10.007
   PubMed Web of Science ®Google Scholar
• Gelatti ACZ, Drilon A, Santini FC. Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC). Lung Cancer. 2019 Nov;137:113–122. doi: 10.1016/j.lungcan.2019.09.017
   PubMed Web of Science ®Google Scholar
• Uribe ML, Marrocco I, Yarden Y. EGFR in cancer: signaling mechanisms, drugs, and acquired resistance. Cancers (Basel). 2021 Jun 1;13(11):2748. doi: 10.3390/cancers13112748
   PubMed Web of Science ®Google Scholar
• Yasuda H, Park E, Yun CH, et al. Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer. Sci, Trans Med. 2013 Dec 18;5(216):216ra177. doi: 10.1126/scitranslmed.3007205
   PubMed Web of Science ®Google Scholar
• Shaul YD, Seger R. The MEK/ERK cascade: from signaling specificity to diverse functions. Biochim Biophys Acta, Mol Cell Res. 2007 Aug;1773(8):1213–1226. doi: 10.1016/j.bbamcr.2006.10.005
   PubMed Web of Science ®Google Scholar
• Katz M, Amit I, Yarden Y. Regulation of MAPKs by growth factors and receptor tyrosine kinases. Biochim Biophys Acta, Mol Cell Res. 2007 Aug;1773(8):1161–1176. doi: 10.1016/j.bbamcr.2007.01.002
   PubMed Web of Science ®Google Scholar
• Hay N, Sonenberg N. Upstream and downstream of mTOR. Genes Dev. 2004 Aug 15;18(16):1926–1945. doi: 10.1101/gad.1212704
   PubMed Web of Science ®Google Scholar
• Simanshu DK, Nissley DV, McCormick F. RAS proteins and their regulators in human disease. Cell. 2017 Jun 29;170(1):17–33. doi: 10.1016/j.cell.2017.06.009.
   PubMed Web of Science ®Google Scholar
• Zheng ZY, Chang EC. A bimolecular fluorescent complementation screen reveals complex roles of endosomes in Ras-mediated signaling. Methods Enzymol. 2014;535:25–38. doi: 10.1016/B978-0-12-397925-4.00002-X
   Google Scholar
• Gimple RC, Wang XR. RAS: striking at the core of the oncogenic circuitry. Front Oncol. 2019;9:965. doi: 10.3389/fonc.2019.00965
   PubMed Web of Science ®Google Scholar
• Moore AR, Rosenberg SC, McCormick F, et al. RAS-targeted therapies: is the undruggable drugged? Nat Rev Drug Discov. 2020 Aug;19(8):533–552. doi: 10.1038/s41573-020-0068-6
   PubMed Web of Science ®Google Scholar
• Healy FM, Prior IA, MacEwan DJ. The importance of Ras in drug resistance in cancer. Br J Pharmacol. 2022 Jun;179(12):2844–2867. doi: 10.1111/bph.15420
   PubMed Web of Science ®Google Scholar
• Wellbrock C, Karasarides M, Marais R. The RAF proteins take centre stage. Nat Rev Mol Cell Biol. 2004 Nov;5(11):875–885. doi: 10.1038/nrm1498
   PubMed Web of Science ®Google Scholar
• Cox AD, Der CJ. The dark side of Ras: regulation of apoptosis. Oncogene. 2003 Dec 8;22(56):8999–9006. doi: 10.1038/sj.onc.1207111
   PubMed Web of Science ®Google Scholar
• Brunet A, Bonni A, Zigmond MJ, et al. Akt promotes cell survival by phosphorylating and inhibiting a forkhead transcription factor. Cell. 1999 Mar 19;96(6):857–868. doi: 10.1016/S0092-8674(00)80595-4
   PubMed Web of Science ®Google Scholar
• Malumbres M, Barbacid M. RAS oncogenes: the first 30 years. Nat Rev Cancer. 2003 Jun 1;3(6):459–465.
   PubMed Web of Science ®Google Scholar
• Prior IA, Hood FE, Hartley JL. The frequency of ras mutations in cancer. Cancer Res. 2020 Jul 15;80(14):2969–2974. doi: 10.1158/0008-5472.CAN-19-3682
   PubMed Web of Science ®Google Scholar
• Tate JG, Bamford S, Jubb HC, et al. COSMIC: the catalogue of somatic mutations in cancer. Nucleic Acids Res. 2019 Jan 8;47(D1):D941–d7. doi: 10.1093/nar/gky1015
   PubMed Web of Science ®Google Scholar
• Forbes SA, Bindal N, Bamford S, et al. COSMIC: mining complete cancer genomes in the catalogue of somatic mutations in cancer. Nucleic Acids Res. 2011 Jan;39(Database issue):D945–50. doi: 10.1093/nar/gkq929
   PubMed Web of Science ®Google Scholar
• Leicht DT, Balan V, Kaplun A, et al. Raf kinases: function, regulation and role in human cancer. Biochim Biophys Acta, Mol Cell Res. 2007 Aug;1773(8):1196–212. doi: 10.1016/j.bbamcr.2007.05.001
   PubMed Web of Science ®Google Scholar
• Rushworth LK, Hindley AD, O’Neill E, et al. Regulation and role of raf-1/B-Raf heterodimerization. Mol Cell Biol. 2006 Mar;26(6):2262–2272. doi: 10.1128/MCB.26.6.2262-2272.2006
   PubMed Web of Science ®Google Scholar
• Moroni M, Veronese S, Benvenuti S, et al. Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. Lancet Oncol. 2005 May;6(5):279–286. doi: 10.1016/S1470-2045(05)70102-9
   PubMed Web of Science ®Google Scholar
• Pai R, Soreghan B, Szabo IL, et al. Prostaglandin E2 transactivates EGF receptor: a novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy. Nat Med. 2002 Mar;8(3):289–293. doi: 10.1038/nm0302-289
   PubMed Web of Science ®Google Scholar
• Darmoul D, Gratio V, Devaud H, et al. Activation of proteinase-activated receptor 1 promotes human colon cancer cell proliferation through epidermal growth factor receptor transactivation. Mol Cancer Res. 2004 Sep;2(9):514–522.
   PubMed Web of Science ®Google Scholar
• Yarom N, Jonker DJ. The role of the epidermal growth factor receptor in the mechanism and treatment of colorectal cancer. Discov Med. 2011 Feb;11(57):95–105.
   PubMed Web of Science ®Google Scholar
• Pellegata NS, Sessa F, Renault B, et al. K-ras and p53 gene mutations in pancreatic cancer: ductal and nonductal tumors progress through different genetic lesions. Cancer Res. 1994 Mar 15;54(6):1556–1560.
   PubMed Web of Science ®Google Scholar
• Deramaudt T, Rustgi AK. Mutant KRAS in the initiation of pancreatic cancer. Biochim Biophys Acta - Rev Cancer. 2005 Nov 25;1756(2):97–101. doi: 10.1016/j.bbcan.2005.08.003
   PubMed Web of Science ®Google Scholar
• ClarivateTM| MetacoreTM – integrated pathway analysis for multi-OMICs data [Internet]. [cited 2023 Sep 1-9]. Available from: https://clarivate.com/cortellis/webinars/metacore-integrated-pathway-analysis-for-multi-omics-data/
   Google Scholar
• KEGG. Kyoto encyclopedia of genes and genomes [Internet]. [cited 2023 Jul 21]. Available from: https://www.genome.jp/kegg/
   Google Scholar
• STRING. Protein-Protein Interaction Networks| Functional Enrichment Analysis [Internet]. [cited 2023 Jul 21]. Available from: https://string-db.org/
   Google Scholar
• Turanli B, Karagoz K, Gulfidan G, et al. A network-based cancer drug discovery: from integrated multi-omics approaches to precision medicine. Curr Pharm Des. 2018;24(32):3778–3790. doi: 10.2174/1381612824666181106095959
   PubMed Web of Science ®Google Scholar
• ClarivateTM| Introducing Cortellis Drug Discovery Intelligence [Internet]. Clarivate. [cited 2023 Sep 1-9]. Available from: https://clarivate.com/cortellis/campaigns/introducing-cortellis-drug-discovery-intelligence/#
   Google Scholar
• Blair HA. Pyrotinib: first global approval. Drugs. 2018 Nov;78(16):1751–1755. doi: 10.1007/s40265-018-0997-0
   PubMed Web of Science ®Google Scholar
• Guan X, Ma F, Li Q, et al. Survival benefit and biomarker analysis of pyrotinib or pyrotinib plus capecitabine for patients with HER2-positive metastatic breast cancer: a pooled analysis of two phase I studies. Biomark Res. 2023 Feb 20;11(1):21. doi: 10.1186/s40364-023-00453-0
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. Identifier: NCT01937689. Study of Pyrotinib in patients with human epidermalgrowth factor receptor 2 (HER2) positive advanced breast cancer [Internet]. [cited 2023 Jun 16]. Available from: https://clinicaltrials.gov/ct2/show/NCT01937689
   Google Scholar
• Zhang X, Li Z, Han L, et al. Efficacy and safety of pyrotinib in human epidermal growth factor receptor 2-positive advanced breast cancer: a multicenter, retrospective, real-world study. Onco Targets Ther. 2022;15:1067–1078. doi: 10.2147/OTT.S379591
   PubMed Web of Science ®Google Scholar
• Zhang Q, He P, Tian T, et al. Real-world efficacy and safety of pyrotinib in patients with HER2-positive metastatic breast cancer: a prospective real-world study. Front Pharmacol. 2023;14:1100556. doi: 10.3389/fphar.2023.1100556
   PubMed Web of Science ®Google Scholar
• Bao Y, Zhang Z, He X, et al. Cost-effectiveness of pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer in China: a scenario analysis of health insurance coverage. Curr Oncol. 2022 Aug 23;29(9):6053–6067. doi: 10.3390/curroncol29090476
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. [Internet] Available from: https://classic.clinicaltrials.gov/ct2/home
   Google Scholar
• Xu B, Yan M, Ma F et al. Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): a multicentre, open-label, randomised, controlled, phase 3 trial. Lancet Oncol. 2021 Mar;22(3):351–360. doi: 10.1016/S1470-2045(20)30702-6
   PubMed Web of Science ®Google Scholar
• Guan X, Ma F, Xu B. Pooled analyses of randomized controlled trials on pyrotinib plus capecitabine and a rethink of the first-line options for HER2-positive relapsed or metastatic breast cancer. Cancer Innovation. 2022;1(2):119–123. doi: 10.1002/cai2.21
   PubMedGoogle Scholar
• Yang G, Xu H, Yang Y, et al. Pyrotinib combined with apatinib for targeting metastatic non-small cell lung cancer with HER2 alterations: a prospective, open-label, single-arm phase 2 study (PATHER2). BMC Med. 2022 Aug 29;20(1):277. doi: 10.1186/s12916-022-02470-6
   PubMed Web of Science ®Google Scholar
• Ahn MJ, Kim HR, Yang JCH, et al. Efficacy and safety of brigatinib compared with crizotinib in Asian vs. non-Asian patients with locally advanced or metastatic ALK-Inhibitor-naive ALK+ non-small cell lung cancer: final results from the phase III ALTA-1L study. Clin Lung Cancer. 2022 Dec;23(8):720–730. doi: 10.1016/j.cllc.2022.07.008
   PubMed Web of Science ®Google Scholar
• Park JW, Liu MC, Yee D, et al. Adaptive randomization of neratinib in early breast cancer. N Engl J Med. 2016;375(1):11–22. doi: 10.1056/NEJMoa1513750
   PubMed Web of Science ®Google Scholar
• Martin M, Holmes FA, Ejlertsen B, et al. Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2017;18(12):1688–1700. doi: 10.1016/S1470-2045(17)30717-9
   PubMed Web of Science ®Google Scholar
• Mukohara T, Hosono A, Mimaki S, et al. Effects of ado-trastuzumab emtansine and fam-trastuzumab deruxtecan on metastatic breast cancer harboring HER2 amplification and the L755S mutation. Oncology. 2021;26(8):635–639. doi: 10.1002/onco.13715
   Google Scholar
• Zeng Q, Wang J, Cheng Z, et al. Discovery and evaluation of clinical Candidate AZD3759, a potent, oral active, central nervous system-penetrant, epidermal growth factor receptor tyrosine kinase inhibitor. J Med Chem. 2015 Oct 22;58(20):8200–8215. doi: 10.1021/acs.jmedchem.5b01073
   PubMed Web of Science ®Google Scholar
• Ahn MJ, Kim DW, Cho BC et al. Activity and safety of AZD3759 in EGFR-mutant non-small-cell lung cancer with CNS metastases (BLOOM): a phase 1, open-label, dose-escalation and dose-expansion study. Lancet Respir Med. 2017 Nov;5(11):891–902. doi: 10.1016/S2213-2600(17)30378-8
   PubMed Web of Science ®Google Scholar
• Zhang Z, Guo X, To KKW, et al. Olmutinib (HM61713) reversed multidrug resistance by inhibiting the activity of ATP-binding cassette subfamily G member 2 in vitro and in vivo. Acta Pharm Sin B. 2018 Jul;8(4):563–574. doi: 10.1016/j.apsb.2018.06.002
   PubMed Web of Science ®Google Scholar
• Zhang W, Fan YF, Cai CY, et al. Olmutinib (BI1482694/HM61713), a novel epidermal growth factor receptor tyrosine kinase inhibitor, reverses ABCG2-mediated multidrug resistance in cancer cells. Front Pharmacol. 2018;9:1097. doi: 10.3389/fphar.2018.01097
   PubMed Web of Science ®Google Scholar
• Park K, Jӓnne PA, Kim DW, et al. Olmutinib in T790M-positive non-small cell lung cancer after failure of first-line epidermal growth factor receptor-tyrosine kinase inhibitor therapy: a global, phase 2 study. Cancer. 2021 May 1;127(9):1407–1416. doi: 10.1002/cncr.33385
   PubMed Web of Science ®Google Scholar
• Hirano T, Yasuda H, Hamamoto J, et al. Pharmacological and structural characterizations of Naquotinib, a novel third-generation EGFR Tyrosine Kinase Inhibitor, in EGFR-Mutated non-small cell lung cancer. Mol Cancer Ther. 2018 Apr;17(4):740–750. doi: 10.1158/1535-7163.MCT-17-1033
   PubMed Web of Science ®Google Scholar
• Murakami H, Nokihara H, Hayashi H, et al. Clinical activity of ASP8273 in Asian patients with non-small-cell lung cancer with EGFR activating and T790M mutations. Cancer Sci. 2018 Sep;109(9):2852–2862. doi: 10.1111/cas.13724
   PubMed Web of Science ®Google Scholar
• Yu HA, Spira A, Horn L, et al. A phase I, dose escalation study of oral ASP8273 in patients with non-small cell lung cancers with epidermal growth factor receptor mutations. Clin Cancer Res. 2017 Dec 15;23(24):7467–7473. doi: 10.1158/1078-0432.CCR-17-1447
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. Identifier: NCT02113813. A dose escalation study of ASP8273 in subjects with non-small-cell lung cancer (NSCLC) who have epidermal growth factor receptor (EGFR) mutations [Internet]. [cited 2023 Jun 14]. Available from: https://clinicaltrials.gov/ct2/show/NCT02113813
   Google Scholar
• Azuma K, Nishio M, Hayashi H, et al. ASP8273 tolerability and antitumor activity in tyrosine kinase inhibitor-naïve Japanese patients with EGFR mutation-positive non-small-cell lung cancer. Cancer Sci. 2018 Aug;109(8):2532–2538. doi: 10.1111/cas.13651
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. Identifier: NCT02588261. A study of ASP8273 vs. Erlotinib or gefitinib in first-line treatment of patients with stage IIIB/IV non-small cell lung cancer tumors with EGFR activating mutations (SOLAR) [Internet]. [cited 2023 Jun 14]. Available from: https://clinicaltrials.gov/ct2/show/NCT02588261
   Google Scholar
• Kelly RJ, Shepherd FA, Krivoshik A, et al. A phase III, randomized, open-label study of ASP8273 versus erlotinib or gefitinib in patients with advanced stage IIIB/IV non-small-cell lung cancer. Ann Oncol. 2019 Jul 1;30(7):1127–1133. doi: 10.1093/annonc/mdz128
   PubMed Web of Science ®Google Scholar
• Wu Q, Jiang H, Wang S, et al. Effects of avitinib on the pharmacokinetics of osimertinib in vitro and in vivo in rats. Thoracic Cancer. 2020 Oct;11(10):2775–2781. doi: 10.1111/1759-7714.13587
   PubMed Web of Science ®Google Scholar
• Wang H, Pan R, Zhang X, et al. Abivertinib in patients with T790M-positive advanced NSCLC and its subsequent treatment with osimertinib. Thoracic Cancer. 2020 Mar;11(3):594–602. doi: 10.1111/1759-7714.13302
   PubMed Web of Science ®Google Scholar
• Xu X. Parallel phase 1 clinical trials in the US and in China: accelerating the test of avitinib in lung cancer as a novel inhibitor selectively targeting mutated EGFR and overcoming T790M-induced resistance. Chin J Cancer. 2015 Jul 08;34(3):285–287. doi: 10.1186/s40880-015-0029-3
   PubMedGoogle Scholar
• Wang H, Zhang L, Zheng X, et al. The ability of avitinib to penetrate the blood brain barrier and its control of intra-/extra- cranial disease in patients of non-small cell lung cancer (NSCLC) harboring EGFR T790M mutation. J Clin Oncol. 2017;35(15_suppl):e20613–e. doi: 10.1200/JCO.2017.35.15_suppl.e20613
   Google Scholar
• Huang S, Li C, Zhang X, et al. Abivertinib synergistically strengthens the anti-leukemia activity of venetoclax in acute myeloid leukemia in a BTK-dependent manner. Mol Oncol. 2020 Oct;14(10):2560–2573. doi: 10.1002/1878-0261.12742
   PubMed Web of Science ®Google Scholar
• Zhou Q, Wu L, Hu P, et al. A novel third-generation EGFR tyrosine kinase inhibitor abivertinib for EGFR T790M-mutant non-small cell lung cancer: a multicenter phase I/II study. Clin Cancer Res. 2022 Mar 15;28(6):1127–1135. doi: 10.1158/1078-0432.CCR-21-2595
   PubMed Web of Science ®Google Scholar
• Jassem J, Dziadziuszko R. Nazartinib in EGFR Thr790Met-mutant non-small-cell lung cancer. Lancet Respir Med. 2020 Jun;8(6):528–529. doi: 10.1016/S2213-2600(19)30361-3
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. Identifier: NCT02108964. A phase I/II, multicenter, open-label study of EGFRmut-TKI EGF816, administered orally in adult patients with EGFRmut solid malignancies [Internet]. [cited 2023 Jun 15]. Available from: https://clinicaltrials.gov/ct2/show/NCT02108964
   Google Scholar
• Cheng H, Nair SK, Murray BW, et al. Discovery of 1-{(3R,4R)-3-[({5-chloro-2-[(1-methyl-1H-pyrazol-4-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-4-yl}oxy)methyl]-4-methoxypyrrolidin-1-yl}prop-2-en-1-one (PF-06459988), a potent, WT sparing, irreversible inhibitor of T790M-Containing EGFR mutants. J Med Chem. 2016 Mar 10;59(5):2005–2024. doi: 10.1021/acs.jmedchem.5b01633
   PubMed Web of Science ®Google Scholar
• Planken S, Behenna DC, Nair SK, et al. Discovery of N-((3R,4R)-4-fluoro-1-(6-((3-methoxy-1-methyl-1H-pyrazol-4-yl)amino)-9-methyl-9H-purin-2-yl)pyrrolidine-3-yl)acrylamide (PF-06747775) through structure-based drug design: a high affinity irreversible inhibitor targeting oncogenic EGFR mutants with selectivity over Wild-Type EGFR. J Med Chem. 2017 Apr 13;60(7):3002–3019. doi: 10.1021/acs.jmedchem.6b01894
   PubMed Web of Science ®Google Scholar
• Yang JC, Camidge DR, Yang CT, et al. Safety, efficacy, and pharmacokinetics of almonertinib (HS-10296) in pretreated patients with EGFR-Mutated advanced NSCLC: a multicenter, open-label, phase 1 trial. J Thorac Oncol. 2020 Dec;15(12):1907–1918. doi: 10.1016/j.jtho.2020.09.001
   PubMed Web of Science ®Google Scholar
• Li Y, Zhou K, Meng Y, et al. Comparison of osimertinib versus Almonertinib in T790M+ EGFR non-small-cell lung cancer patients. J Clin Pharm Ther. 2023 Mar 28;2023:1–5. doi: 10.1155/2023/3028257
   Web of Science ®Google Scholar
• Lu S, Dong X, Jian H, et al. AENEAS: a randomized phase III trial of aumolertinib versus gefitinib as first-line therapy for locally advanced or MetastaticNon-small-cell lung cancer with EGFR exon 19 deletion or L858R mutations. J Clin Oncol. 2022 Sep 20;40(27):3162–3171. doi: 10.1200/JCO.21.02641
   PubMed Web of Science ®Google Scholar
• Dhillon S. Lazertinib: First Approval. Drugs. 2021 Jun;81(9):1107–1113. doi: 10.1007/s40265-021-01533-x
   PubMed Web of Science ®Google Scholar
• Heppner DE, Wittlinger F, Beyett TS, et al. Structural basis for inhibition of mutant EGFR with lazertinib (YH25448). ACS Med Chem Lett. 2022 Dec 08;13(12):1856–1863. doi: 10.1021/acsmedchemlett.2c00213
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. Identifier: NCT04077463. A study of Lazertinib as monotherapy or in combination with amivantamab in participants with advanced non-small cell lung cancer (chrysalis-2) [Internet]. [cited 2023 Jun 19]. Available from: https://clinicaltrials.gov/ct2/show/NCT04077463
   Google Scholar
• Ahn MJ, Han JY, Lee KH, et al. Lazertinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: results from the dose escalation and dose expansion parts of a first-in-human, open-label, multicentre, phase 1-2 study. Lancet Oncol. 2019 Dec;20(12):1681–1690. doi: 10.1016/S1470-2045(19)30504-2
   PubMed Web of Science ®Google Scholar
• Lamb YN. Osimertinib: a review in Previously untreated, EGFR mutation-positive, advanced NSCLC. Targeted Oncol. 2021 Sep;16(5):687–695. doi: 10.1007/s11523-021-00839-w
   PubMed Web of Science ®Google Scholar
• Frampton JE. Osimertinib: a review in completely resected, early-stage, EGFR mutation-positive NSCLC. Targeted Oncol. 2022 May;17(3):369–376. doi: 10.1007/s11523-022-00883-0
   PubMed Web of Science ®Google Scholar
• Di Noia V, A D, E D, et al. Treating disease progression with osimertinib in EGFR-mutated non-small-cell lung cancer: novel targeted agents and combination strategies. ESMO Open. 2021 Dec;6(6):100280. doi: 10.1016/j.esmoop.2021.100280
   PubMed Web of Science ®Google Scholar
• Remon J, Steuer CE, Ramalingam SS, et al. Osimertinib and other third-generation EGFR TKI in EGFR-mutant NSCLC patients. Ann Oncol. 2018 Jan 1;29(suppl_1):i20–i7. doi: 10.1093/annonc/mdx704
   PubMedGoogle Scholar
• Menis J, Remon J. Befotertinib—a viable alternative in EGFR-mutant advanced NSCLC? Lancet Respir Med. 2023 May 24;(10):857–859. doi: 10.1016/S2213-2600(23)00216-3
   PubMed Web of Science ®Google Scholar
• Lu S, Zhou J, Jian H, et al. Befotertinib (D-0316) versus icotinib as first-line therapy for patients with EGFR-mutated locally advanced or metastatic non-small-cell lung cancer: a multicentre, open-label, randomised phase 3 study. Lancet Respir Med. 2023 May 24;11(10):905–915. doi: 10.1016/S2213-2600(23)00183-2
   PubMed Web of Science ®Google Scholar
• Li B, Wu L, Pan Y, et al. Efficacy and safety of ASK120067 (limertinib) in patients with locally advanced or metastatic EGFR T790M-mutated non–small cell lung cancer: a multicenter, single-arm, phase IIb study. J Clin Oncol. 2022;40(16_suppl):9106. doi: 10.1200/JCO.2022.40.16_suppl.9106
   Web of Science ®Google Scholar
• Shi Y, Li B, Wu L, et al. Efficacy and safety of Limertinib (ASK120067) in patients with locally advanced or metastatic EGFR Thr790Met-mutated NSCLC: a multicenter, single-arm, phase 2b study. J Thorac Oncol. 2022 Oct;17(10):1205–1215. doi: 10.1016/j.jtho.2022.05.011
   PubMed Web of Science ®Google Scholar
• Jia Y, Yun CH, Park E, et al. Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors. Nature. 2016 Jun 2;534(7605):129–132. doi: 10.1038/nature17960
   PubMed Web of Science ®Google Scholar
• Zhao P, Yao MY, Zhu SJ, et al. Crystal structure of EGFR T790M/C797S/V948R in complex with EAI045. Biochem Biophys Res Commun. 2018 Jul 20;502(3):332–337. doi: 10.1016/j.bbrc.2018.05.154
   PubMed Web of Science ®Google Scholar
• To C, Jang J, Chen T, et al. Single and dual targeting of mutant EGFR with an allosteric inhibitor. Cancer Discovery. 2019 Jul;9(7):926–943. doi: 10.1158/2159-8290.CD-18-0903
   PubMed Web of Science ®Google Scholar
• Niggenaber J, Heyden L, Grabe T, et al. Complex Crystal Structures of EGFR with third-generation kinase inhibitors and simultaneously bound allosteric ligands. ACS Med Chem Lett. 2020 Dec 10;11(12):2484–2490. doi: 10.1021/acsmedchemlett.0c00472
   PubMed Web of Science ®Google Scholar
• To C, Beyett TS, Jang J, et al. An allosteric inhibitor against the therapy-resistant mutant forms of EGFR in non-small cell lung cancer. Nat Cancer. 2022 Apr;3(4):402–417. doi: 10.1038/s43018-022-00351-8
   PubMedGoogle Scholar
• Siddiqui AJ, Jahan S, Patel M, et al. Identifying novel and potent inhibitors of EGFR protein for the drug development against the breast cancer. J Biomol Struct Dyn. 2023;41(23):14460–14472. doi: 10.1080/07391102.2023.2181646
   PubMed Web of Science ®Google Scholar
• Fu K, Xie F, Wang F, et al. Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance. J Hematol Oncol. 2022 Dec 08;15(1):173. doi: 10.1186/s13045-022-01391-4
   PubMed Web of Science ®Google Scholar
• Kitadai R, Okuma Y. Treatment strategies for non-small cell lung cancer harboring common and uncommon EGFR mutations: drug sensitivity based on Exon Classification, and structure-function analysis. Cancers (Basel). 2022;14(10):2519. doi: 10.3390/cancers14102519
   PubMed Web of Science ®Google Scholar
• Eno MS, Brubaker JD, Campbell JE, et al. Discovery of BLU-945, a reversible, potent, and wild-type-sparing next-generation EGFR mutant inhibitor for treatment-resistant non-small-cell lung cancer. J Med Chem. 2022 Jul 28;65(14):9662–9677. doi: 10.1021/acs.jmedchem.2c00704
   PubMedGoogle Scholar
• Shi F, Liu Y, Zhou X, et al. Disitamab vedotin: a novel antibody-drug conjugates for cancer therapy. Drug Delivery. 2022 Dec;29(1):1335–1344. doi: 10.1080/10717544.2022.2069883
   PubMed Web of Science ®Google Scholar
• Chen M, Yao K, Cao M, et al. HER2-targeting antibody-drug conjugate RC48 alone or in combination with immunotherapy for locally advanced or metastatic urothelial carcinoma: a multicenter, real-world study. Cancer Immunol Immunother. 2023 Jul;72(7):2309–2318. doi: 10.1007/s00262-023-03419-1
   PubMed Web of Science ®Google Scholar
• Powles T, Yu EY, Iyer G, et al. Phase 2 clinical study evaluating the efficacy and safety of disitamab vedotin with or without pembrolizumab in patients with HER2-expressing urothelial carcinoma (RC48G001). J Clin Oncol. 2023;41(6_suppl):TPS594–TPS. doi: 10.1200/JCO.2023.41.6_suppl.TPS594
   Google Scholar
• Miyanaga A, Asahina H, Watanabe S, et al. A phase I/II study of necitumumab plus pembrolizumab, Nab-Paclitaxel, and carboplatin for Previously untreated advanced squamous non-small cell lung cancer study: (NEJ048A/NEXUS). Clin Lung Cancer. 2023 Jun;24(4):371–375. doi: 10.1016/j.cllc.2023.01.008
   PubMed Web of Science ®Google Scholar
• Koyama K, Ishikawa H, Abe M, et al. Patritumab deruxtecan (HER3-DXd), a novel HER3 directed antibody drug conjugate, exhibits in vitro activity against breast cancer cells expressing HER3 mutations with and without HER2 overexpression. PloS One. 2022;17(5):e0267027. doi: 10.1371/journal.pone.0267027
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. Identifier: NCT05338970. HERTHENA-Lung02: a study of patritumab deruxtecan versus platinum-based chemotherapy in metastatic or locally advanced EGFRm NSCLC after failure of EGFR TKI therapy [Internet]. [cited 2023 Jul 5]. Available from: https://classic.clinicaltrials.gov/ct2/show/NCT05338970
   Google Scholar
• Lim SM, Kim CG, Lee JB, et al. Patritumab Deruxtecan: paving the way for EGFR-TKI-Resistant NSCLC. Cancer Discovery. 2022 Jan;12(1):16–19. doi: 10.1158/2159-8290.CD-21-1429
   PubMed Web of Science ®Google Scholar
• Yonesaka K, Tanizaki J, Maenishi O, et al. HER3 augmentation via blockade of EGFR/AKT signaling enhances anticancer activity of HER3-targeting patritumab deruxtecan in EGFR-mutated non-small cell lung cancer. Clin Cancer Res. 2022 Jan 15;28(2):390–403. doi: 10.1158/1078-0432.CCR-21-3359
   PubMed Web of Science ®Google Scholar
• Meric-Bernstam F, Beeram M, Hamilton E, et al. Zanidatamab, a novel bispecific antibody, for the treatment of locally advanced or metastatic HER2-expressing or HER2-amplified cancers: a phase 1, dose-escalation and expansion study. Lancet Oncol. 2022 Dec;23(12):1558–1570. doi: 10.1016/S1470-2045(22)00621-0
   PubMed Web of Science ®Google Scholar
• Harding JJ, Fan J, Oh DY, et al. Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study. Lancet Oncol. 2023 Jun 2;24(7):772–782. doi: 10.1016/S1470-2045(23)00242-5
   PubMed Web of Science ®Google Scholar
• Skoulidis F, Li BT, Dy GK, et al. Sotorasib for lung cancers with KRAS p.G12C mutation. N Engl J Med. 2021 Jun 24;384(25):2371–2381. doi: 10.1056/NEJMoa2103695
   PubMed Web of Science ®Google Scholar
• Blair HA. Sotorasib: First Approval. Drugs. 2021 Sep;81(13):1573–1579. doi: 10.1007/s40265-021-01574-2
   PubMed Web of Science ®Google Scholar
• Strickler JH, Satake H, George TJ, et al. Sotorasib in KRAS p.G12C-Mutated advanced pancreatic cancer. N Engl J Med. 2023 Jan 5;388(1):33–43. doi: 10.1056/NEJMoa2208470
   PubMed Web of Science ®Google Scholar
• Lee A. Sotorasib: A Review in KRAS G12C Mutation-Positive Non-small Cell Lung Cancer. Targeted Oncol. 2022 Nov;17(6):727–733. doi: 10.1007/s11523-022-00922-w
   PubMed Web of Science ®Google Scholar
• Nakajima EC, Drezner N, Li X, et al. FDA approval summary: sotorasib for KRAS G12C-Mutated metastatic NSCLC. Clin Cancer Res. 2022 Apr 14;28(8):1482–1486. doi: 10.1158/1078-0432.CCR-21-3074
   PubMed Web of Science ®Google Scholar
• Zheng X, Luo J, Liu W, et al. Sotorasib: a treatment for non-small cell lung cancer with the KRAS G12C mutation. Drugs Today (Barc). 2022 Apr;58(4):175–185. doi: 10.1358/dot.2022.58.4.3400573
   PubMed Web of Science ®Google Scholar
• Weiss A, Lorthiois E, Barys L, et al. Discovery, preclinical characterization, and early clinical activity of JDQ443, a structurally novel, potent, and selective covalent oral inhibitor of KRASG12C. Cancer Discovery. 2022 Jun 2;12(6):1500–1517. doi: 10.1158/2159-8290.CD-22-0158
   PubMed Web of Science ®Google Scholar
• Kwan AK, Piazza GA, Keeton AB, et al. The path to the clinic: a comprehensive review on direct KRASG12C inhibitors. J Exp Clin Cancer Res. 2022 Jan 19;41(1):27. doi: 10.1186/s13046-021-02225-w
   PubMed Web of Science ®Google Scholar
• Purkey H. Abstract ND11: discovery of GDC-6036, a clinical stage treatment for KRAS G12C-positive cancers. Cancer Res. 2022;82(12_Supplement):ND11–ND. doi: 10.1158/1538-7445.AM2022-ND11
   Web of Science ®Google Scholar
• Xu J, Lim N-K, Timmerman JC, et al. Second-generation atroposelective synthesis of KRAS G12C covalent inhibitor GDC-6036. Org Lett. 2023 May 19;25(19):3417–3422. doi: 10.1021/acs.orglett.3c00961
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. Identifier: NCT04449874. A study to evaluate the safety, pharmacokinetics, and activity of GDC-6036 alone or in combination in participants with advanced or metastatic solid tumors with a KRAS G12C mutation [Internet]. [cited 2023 Jul 6]. Available from: https://classic.clinicaltrials.gov/ct2/show/NCT04449874
   Google Scholar
• Desai J, Han S-W, Lee J-S, et al. Abstract CT029: phase ib study of GDC-6036 in combination with cetuximab in patients with colorectal cancer (CRC) with KRAS G12C mutation. Cancer Res. 2023;83(8_Supplement):CT029–CT. doi: 10.1158/1538-7445.AM2023-CT029
   Web of Science ®Google Scholar
• Desai J, Han S-W, Forster M, et al. 362P phase ia study to evaluate GDC-6036 monotherapy in patients with colorectal cancer (CRC) with KRAS G12C mutation. Ann Oncol. 2022;33:S701–S2. doi: 10.1016/j.annonc.2022.07.500
   Google Scholar
• Patel M, Lee J, De Miguel M, et al. 459MO phase ia study to evaluate GDC-6036 monotherapy in patients with solid tumors with a KRAS G12C mutation. Ann Oncol. 2022;33:S749. doi: 10.1016/j.annonc.2022.07.588
   Google Scholar
• Wang X, Allen S, Blake JF, et al. Identification of MRTX1133, a Noncovalent, Potent, and Selective KRAS(G12D) Inhibitor. J Med Chem. 2022 Feb 24;65(4):3123–3133. doi: 10.1021/acs.jmedchem.1c01688
   PubMedGoogle Scholar
• Issahaku AR, Mukelabai N, Agoni C, et al. Characterization of the binding of MRTX1133 as an avenue for the discovery of potential KRAS(G12D) inhibitors for cancer therapy. Sci Rep. 2022 Oct 22;12(1):17796. doi: 10.1038/s41598-022-22668-1
   PubMed Web of Science ®Google Scholar
• Kemp SB, Cheng N, Markosyan N, et al. Efficacy of a small-molecule inhibitor of KrasG12D in immunocompetent models of pancreatic cancer. Cancer Discovery. 2023 Feb 6;13(2):298–311. doi: 10.1158/2159-8290.CD-22-1066
   PubMed Web of Science ®Google Scholar
• Shi Z, Weng J, Fan X, et al. Abstract 932: discovery of D-1553, a novel and selective KRas-G12C Inhibitor with potent anti-tumor activity in a broad spectrum of tumor cell lines and xenograft models. Cancer Res. 2021;81(13_Supplement):932. doi: 10.1158/1538-7445.AM2021-932
   Google Scholar
• Shi Z, Weng J, Niu H, et al. D-1553: a novel KRASG12C inhibitor with potent and selective cellular and in vivo antitumor activity. Cancer Sci. 2023;114(7):2951–2960. doi: 10.1111/cas.15829
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. Identifier: NCT04585035. Study to evaluate D-1553 in subjects with solid tumors [Internet]. [cited 2023 Jul 8]. Available from: https://classic.clinicaltrials.gov/ct2/show/NCT04585035
   Google Scholar
• Li Z, Jiang K, Zhu X, et al. Encorafenib (LGX818), a potent BRAF inhibitor, induces senescence accompanied by autophagy in BRAFV600E melanoma cells. Cancer Lett. 2016 Jan 28;370(2):332–344. doi: 10.1016/j.canlet.2015.11.015
   PubMed Web of Science ®Google Scholar
• Koelblinger P, Thuerigen O, Dummer R. Development of encorafenib for BRAF-mutated advanced melanoma. Curr Opin Oncol. 2018 Mar;30(2):125–133. doi: 10.1097/CCO.0000000000000426
   PubMed Web of Science ®Google Scholar
• Henry JT, Coker O, Chowdhury S, et al. Comprehensive clinical and molecular characterization of KRAS G12C-mutant colorectal cancer. JCO Precis Oncol. 2021;5(5):613–621. doi: 10.1200/PO.20.00256
   Google Scholar
• Amodio V, Yaeger R, Arcella P, et al. EGFR blockade reverts resistance to KRASG12C inhibition in colorectal cancer. Cancer Discov. 2020;10(8):1129–1139. doi: 10.1158/2159-8290.CD-20-0187
   PubMed Web of Science ®Google Scholar
• Rheault TR, Stellwagen JC, Adjabeng GM, et al. Discovery of Dabrafenib: a selective inhibitor of Raf Kinases with antitumor activity against B-Raf-driven tumors. ACS Med Chem Lett. 2013 Mar 14;4(3):358–362. doi: 10.1021/ml4000063
   PubMed Web of Science ®Google Scholar
• Ascierto PA, Ferrucci PF, Fisher R, et al. Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma. Nature Med. 2019;25(6):941–946. doi: 10.1038/s41591-019-0448-9
   PubMed Web of Science ®Google Scholar
• Dummer R, Long GV, Robert C, et al. Randomized Phase III Trial Evaluating Spartalizumab Plus Dabrafenib and Trametinib for BRAF V600-Mutant Unresectable or Metastatic Melanoma. J Clin Oncol. 2022 May 1;40(13):1428–1438. doi: 10.1200/JCO.21.01601
   PubMed Web of Science ®Google Scholar
• Stachyra‑Strawa P, Ciesielka M, Janiszewski M, et al. The role of immunotherapy and molecular‑targeted therapy in the treatment of melanoma. Oncol Rep. 2021;46(2):1–12. doi: 10.3892/or.2021.8109
   Web of Science ®Google Scholar
• Cox AD, Der CJ. The RAF inhibitor paradox revisited. Cancer Cell. 2012 Feb 14;21(2):147–149. doi: 10.1016/j.ccr.2012.01.017
   PubMed Web of Science ®Google Scholar
• Marjomäki V, Laajala M, Martikainen M, inventorsVemurafenib and salts thereof for use in the treatment of enteroviral infections. World Patent, WO/2020/070390. 2020 Apr 9.
   Google Scholar
• Rasco DW, Medina T, Corrie P, et al. Phase 1 study of the pan-RAF inhibitor tovorafenib in patients with advanced solid tumors followed by dose expansion in patients with metastatic melanoma. Cancer Chemother Pharmacol. 2023 Jul;92(1):15–28. doi: 10.1007/s00280-023-04544-5
   PubMed Web of Science ®Google Scholar
• Zhang HL, Li Y. The Patent Landscape of BRAF Target and KRAS Target. Recent patents on anti-cancer drug discovery. Recent Patents Anti-Cancer Drug Disc. 2023;18(4):495–505. doi: 10.2174/1574892818666221207091329
   PubMed Web of Science ®Google Scholar
• Lacouture ME, Wainberg ZA, Patel AB, et al. Reducing skin toxicities from EGFR inhibitors with topical BRAF inhibitor therapy. Cancer Discov. 2021 Sep;11(9):2158–2167 doi: 10.1158/2159-8290.CD-20-1847
   PubMed Web of Science ®Google Scholar
• Tkacik E, Li K, Gonzalez-Del Pino G, et al. Structure and RAF family kinase isoform selectivity of type II RAF inhibitors tovorafenib and naporafenib. J Biol Chem. 2023 May;299(5):104634. doi: 10.1016/j.jbc.2023.104634
   PubMed Web of Science ®Google Scholar
• de Braud F, Dooms C, Heist RS, et al. Initial evidence for the efficacy of naporafenib in combination with trametinib in NRAS-mutant melanoma: results from the expansion arm of a phase ib, open-label study. J Clin Oncol. 2023;41(14):2651–2660. doi: 10.1200/JCO.22.02018
   PubMed Web of Science ®Google Scholar
• Ohoka N, Suzuki M, Uchida T, et al. Development of a potent small-molecule degrader against oncogenic BRAF(V600E) protein that evades paradoxical MAPK activation. Cancer Sci. 2022 Aug;113(8):2828–2838. doi: 10.1111/cas.15401
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. Identifier: NCT05503797. A study to assess the efficacy and safety of FORE8394 in participants with cancer harboring BRAF alterations [Internet]. (cited 2023 Sep 5]. Available from: https://classic.clinicaltrials.gov/ct2/show/NCT05503797
   Google Scholar
• Ono H, Horinaka M, Sukeno M, et al. Novel RAF/MEK inhibitor CH5126766/VS-6766 has efficacy in combination with eribulin for the treatment of triple-negative breast cancer. Cancer Sci. 2021 Oct;112(10):4166–4175.doi: 10.1111/cas.15071
   PubMed Web of Science ®Google Scholar
• Capelletto E, Bironzo P, Denis L, et al. Single agent VS-6766 or VS-6766 plus defactinib in KRAS-mutant non-small-cell lung cancer: the RAMP-202 phase II trial. Future Oncol. 2022;18(16):1907–1915. doi: 10.2217/fon-2021-1582
   PubMed Web of Science ®Google Scholar
• Yuan X, Zhang X, Du R, et al. Abstract 6415: RAF dimer inhibitor lifirafenib enhances the antitumor activity of MEK inhibitor mirdametinib in RAS mutant tumors. Cancer Res. 2020;80(16_Supplement):6415. doi: 10.1158/1538-7445.AM2020-6415
   Web of Science ®Google Scholar
• Desai J, Gan H, Barrow C, et al. Phase I, open-label, dose-Escalation/Dose-expansion study of lifirafenib (BGB-283), an RAF family kinase inhibitor, in patients with solid tumors. J Clin Oncol. 2020 Jul 1;38(19):2140–2150. doi: 10.1200/JCO.19.02654
   PubMed Web of Science ®Google Scholar
• Awada G, Neyns B. Melanoma with genetic alterations beyond the BRAF V600 mutation: management and new insights. Curr Opin Oncol. 2022;34(2):115–122. doi: 10.1097/CCO.0000000000000817
   PubMed Web of Science ®Google Scholar
• Li J, Li X, Dong N, et al. Driver and targetable alterations in Chinese patients with small bowel carcinoma. J Cancer Res Clin Oncol. 2023;149(9):6139–6150. doi: 10.1007/s00432-022-04521-0
   PubMed Web of Science ®Google Scholar
• Gouda MA, Subbiah V. Precision oncology for BRAF-mutant cancers with BRAF and MEK inhibitors: from melanoma to tissue-agnostic therapy. ESMO Open. 2023 Apr 1;8(2):100788. doi: 10.1016/j.esmoop.2023.100788
   PubMed Web of Science ®Google Scholar
• Yen I, Shanahan F, Lee J, et al. ARAF mutations confer resistance to the RAF inhibitor belvarafenib in melanoma. Nature. 2021;594(7863):418–423. doi: 10.1038/s41586-021-03515-1
   PubMed Web of Science ®Google Scholar
• Cross DA, Ashton SE, Ghiorghiu S, et al. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discovery. 2014 Sep;4(9):1046–1061. doi: 10.1158/2159-8290.CD-14-0337
   PubMed Web of Science ®Google Scholar
• Leonetti A, Sharma S, Minari R, et al. Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer. Br J Cancer. 2019 Oct;121(9):725–737. doi: 10.1038/s41416-019-0573-8
   PubMed Web of Science ®Google Scholar
• Balko JM, Jones BR, Coakley VL, et al. MEK and EGFR inhibition demonstrate synergistic activity in EGFR-dependent NSCLC. Cancer Biol Ther. 2009 Mar 15;8(6):522–530. doi: 10.4161/cbt.8.6.7690
   PubMed Web of Science ®Google Scholar
• Kim D, Xue JY, Lito P. Targeting KRAS(G12C): from inhibitory mechanism to modulation of antitumor effects in patients. Cell. 2020 Nov 12;183(4):850–859. doi: 10.1016/j.cell.2020.09.044
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Yaeger R, Delord JP, et al. Phase Ib/II study of the efficacy and safety of binimetinib (MEK162) plus Panitumumab for mutant or wild-type RAS metastatic colorectal cancer. Oncology. 2023 Dec 11;28(12):e1209–e18. doi: 10.1093/oncolo/oyad210
   Google Scholar
• Fawwaz M, Mishiro K, Nishii R, et al. Synthesis and fundamental evaluation of radioiodinated rociletinib (CO-1686) as a probe to lung cancer with L858R/T790M mutations of epidermal growth factor receptor (EGFR). Molecules (Basel, Switzerland). 2020 Jun 24;25(12). doi: 10.3390/molecules25122914
   PubMed Web of Science ®Google Scholar
• Shi S, Du Y, Huang L, et al. Discovery of novel potent covalent inhibitor-based EGFR degrader with excellent in vivo efficacy. Bioorg Chem. 2022 Mar;120:105605. doi: 10.1016/j.bioorg.2022.105605
   PubMed Web of Science ®Google Scholar
• Jang J, To C, De Clercq DJH, et al. Mutant-Selective Allosteric EGFR Degraders are effective against a broad range of drug-resistant mutations. Angew Chem Int Ed Engl. 2020 Aug 17;59(34):14481–14489. doi: 10.1002/anie.202003500
   PubMed Web of Science ®Google Scholar
• Zhang H, Xie R, Ai-Furas H, et al. Design, synthesis, and biological evaluation of novel EGFR PROTACs targeting Del19/T790M/C797S mutation. ACS Med Chem Lett. 2022 Feb 10;13(2):278–283. doi: 10.1021/acsmedchemlett.1c00645
   PubMed Web of Science ®Google Scholar
• Zhao HY, Wang HP, Mao YZ, et al. Discovery of potent PROTACs targeting EGFR mutants through the optimization of covalent EGFR ligands. J Med Chem. 2022 Mar 24;65(6):4709–4726. doi: 10.1021/acs.jmedchem.1c01827
   PubMed Web of Science ®Google Scholar
• Yang N, Fan Z, Sun S, et al. Discovery of highly potent and selective KRAS(G12C) degraders by VHL-recruiting PROTACs for the treatment of tumors with KRAS(G12C)-mutation. Eur J Med Chem. 2023 Dec 5;261:115857. doi: 10.1016/j.ejmech.2023.115857
   PubMed Web of Science ®Google Scholar
• Zeng M, Xiong Y, Safaee N, et al. Exploring targeted degradation strategy for oncogenic KRAS(G12C). Cell Chem Biol. 2020 Jan 16;27(1):19–31.e6. doi: 10.1016/j.chembiol.2019.12.006
   PubMed Web of Science ®Google Scholar
• Marini E, Marino M, Gionfriddo G, et al. Investigation into the use of encorafenib to develop potential PROTACs directed against BRAF(V600E) protein. Molecules (Basel, Switzerland). 2022 Dec 3;27(23):8513. doi: 10.3390/molecules27238513
   PubMed Web of Science ®Google Scholar